Products

DeepRhythmAI
Medicalgorithmics S.A.
Cardiology AI
DeepRhythmAI is an FDA-cleared, cloud-based AI algorithm by Medicalgorithmics S.A. that revolutionizes cardiac arrhythmia detection and classification from ECG data, offering superior accuracy and efficiency for physicians.

See all 1 product →

About Medicalgorithmics

Medicalgorithmics is a medical technology company specializing in advanced, AI-powered, and non-invasive solutions for cardiac diagnostics. Their core offerings include sophisticated algorithms, software platforms, and medical devices designed for the precise detection and analysis of cardiac arrhythmias and the assessment of coronary artery disease. Key products such as PocketECG provide continuous, long-term ECG monitoring with comprehensive diagnostic reports, while the FDA-approved DeepRhythmAI (DRAI) engine offers accurate, real-time heart rhythm analysis.

The company also develops the DeepRhythm Platform (DRP), a cloud-based, hardware-agnostic platform for ECG data analysis, classification, and reporting, facilitating real-time data exchange for physicians globally. Furthermore, their innovative VCAST (Virtual Cardiac Stress Test) utilizes AI-powered, non-invasive CT-based analysis to assess coronary artery stenosis and blood flow significance, aiming to revolutionize the diagnosis and treatment of coronary artery disease. Medicalgorithmics leverages an extensive ECG database with billions of annotated heartbeats and predictive analytics to enhance diagnostic accuracy and support personalized patient care.

What Physicians Need to Know

Cardiac Arrhythmia Diagnostics
Medicalgorithmics specializes in AI-powered solutions for detecting, classifying, analyzing, and reporting cardiac arrhythmias. Their flagship products, PocketECG, DeepRhythmAI (DRAI), and DeepRhythm Platform (DRP), offer comprehensive ECG analysis.
Non-invasive Cardiac Diagnostics
The company focuses on non-invasive AI-powered solutions for cardiac diagnostics, including their Virtual Cardiac Stress Test (VCAST) for analyzing CT-scan data to assess coronary artery disease.
AI/ML Algorithm Development
Medicalgorithmics has extensive experience in developing complex AI/ML algorithms for analyzing physiological signals like ECGs and cardiac images, with DeepRhythmAI being a testament to their expertise.
Cloud-based Platforms
Their DeepRhythm Platform (DRP) is a hardware-agnostic, cloud-based software solution for ECG data analysis, classification, and reporting.
Medical Device & Software Development
They develop and distribute innovative medical devices such as PocketECG and Kardiobeat.ai (Holter monitors), alongside their advanced software solutions.
Physician Tip

For physicians, Medicalgorithmics offers unparalleled diagnostic confidence through superior data and reporting with the highest diagnostic yield available. Their 'True Full Disclosureu2122' provides complete heartbeat analysis, full arrhythmia detection, arrhythmia burden calculation, accurate PVC and PAC counts, and symptom correlation, enabling more informed decisions and better patient outcomes. The AI-driven DeepRhythmAI significantly reduces report generation time (by up to 50%), allowing for faster diagnosis and treatment planning, and supports near-real-time intervention. The ease of use for patients with devices like PocketECG, combined with seamless EHR integration tools, streamlines practice workflows. Furthermore, their hardware-agnostic software solutions provide flexibility, allowing integration with various third-party devices and potentially reducing operational costs for healthcare providers.

Medicalgorithmics is actively pursuing a strategy of developing and selling standalone analytical software products designed for seamless integration with third-party medical equipment. Their DeepRhythmAI (DRAI) and DeepRhythm Platform (DRP) are built to be hardware-agnostic, allowing integration with various wearable ECG monitoring devices, including their own PocketECG and Kardiobeat.ai, as well as devices from other manufacturers like DMS and Bittium Faros. They have established partnerships with companies like livetec Ingenieurbu00fcro GmbH and Zenicor Medical Systems AB to integrate their AI algorithms and platforms into their respective ECG monitoring systems. This approach broadens their market reach and offers clients flexibility in leveraging their existing medical technology infrastructure.

Products by Medicalgorithmics

1 product in the directory

DeepRhythmAI
Medicalgorithmics S.A.
Cardiology AI
DeepRhythmAI is an FDA-cleared, cloud-based AI algorithm by Medicalgorithmics S.A. that revolutionizes cardiac arrhythmia detection and classification from ECG data, offering superior accuracy and efficiency for physicians.

What the Web Says

Medicalgorithmics specializes in AI-powered cardiac diagnostic solutions, offering systems for long-term ECG monitoring and remote patient monitoring. Their PocketECG solution is highlighted for its advanced algorithms, full-disclosure ECG data, and ability to correlate physical activity with arrhythmia. While product reviews emphasize the technology's capabilities, employer reviews present a mixed picture regarding recruitment, compensation, and career advancement.

Overall: Mixed

Strengths

  • Advanced AI algorithms for accurate arrhythmia detection and analysis.
  • PocketECG provides full-disclosure ECG data and detailed statistical reports.
  • Ability to correlate physical activity with arrhythmia and symptoms.
  • User-friendly interface and effortless setup for patients using PocketECG.
  • Seamless flexibility to switch between different monitoring modes without device change.
  • Continuous technical support for patients.

Limitations

  • Recruitment process can be lengthy and lead to last-minute rejections.
  • Compensation may be considered low, especially for entry-level hybrid roles.
  • Potential for high employee turnover and low morale in some departments.
  • Limited opportunities for advancement within the company.
  • Some existing ECG interpretation software is already quite good, making it a competitive market for new AI solutions.
  • Lack of interoperability with other medical software can be a challenge for healthcare IT solutions.

Based on reviews from: DAIC, GoWork.pl, Indeed.com, PVMEDIPOINT, Danelfin, BioSpace, Reddit

Last updated: 2026-07-19

Videos

News, demos, and interviews about Medicalgorithmics.

Loading videos...

Videos load interactively. If none appear, search YouTube for Medicalgorithmics →

View all on YouTube

Press & Coverage

Poland Insight
Medicalgorithmics records dynamic revenue growth from AI services in the USA and continues business model transformation
Medicalgorithmics continued its business model transformation in the first half of 2024, focusing on acquiring new customers and increasing sales of AI-based EKG analysis services in the USA. The company gained 13 new partners, including five in the USA, and saw a significant increase in revenue from AI services.
2024-09
MarketScreener
Medicalgorithmics S A : Starts Providing ECG Cardiac Safety Services Using AI in a Clinical Trial for a New Drug
Medicalgorithmics has begun providing cardiac safety services for a new drug's clinical trial, utilizing its AI software and ECG diagnostic devices for real-time remote monitoring of patient heart function. This is part of the company's strategy to expand its commercial involvement in clinical trials as a new revenue stream.
2024-03
MoneyController
Medicalgorithmics to increase engagement in key projects Funding support from BioFund
Medicalgorithmics and BioFund signed an agreement for an additional $2.4 million in financing, increasing the total loan value to $5.4 million. This funding aims to support the company's expansion strategy and achieve profitability by 2026.
2025-04
Reuters
Brief: Medicalgorithmics Signs LOI To Develop Robotic System For Heart Defect Treatment
Medicalgorithmics SA signed a Letter of Intent with Fundacja Rozwoju Kardiochirurgii im. Zbigniewa Religi and BioFund Capital Management LLC to potentially develop a robotic system for treating structural heart defects. The project will cover design, software for medical imaging analysis, and robotic systems.
2026-05
Poland Insight
Medicalgorithmics to Convert More Than PLN 16 Million of Debt Into Shares
Medicalgorithmics will reduce its debt by over PLN 16 million through the issuance of more than 500,000 new shares to Biofund Capital Management, which will acquire them in exchange for canceling loan liabilities. This transaction, approved by an Extraordinary General Meeting, will significantly improve the company's balance sheet.
2026-07
Perplexity
Medicalgorithmics S.A. Price: Quote, Forecast, Charts & News (MDG.WA)
Medicalgorithmics S.A. is a Warsaw-listed Polish medical technology company specializing in AI-powered and non-invasive solutions for cardiac arrhythmia diagnostics. The company has transformed into a capital-light AI software business, with services now representing approximately 94% of revenue.
2026-07
MarketScreener
Medicalgorithmics S A : is entering a business talks with a global MedTech company listed on the NYSE with a multi-billion-dollar business
Medicalgorithmics is in talks with a global MedTech company listed on the NYSE for potential collaboration on ambulatory cardiac diagnostics using Medicalgorithmics' proprietary AI-based technologies. The discussions include retrospective ECG analysis services and Mobile Cardiac Telemetry (MCT) solutions.
2026-06
PAP MediaRoom
MEDICALGORITHMICS SA (30/2026) 10,8 mln zu0142 przychodu00f3w ze sprzedau017cy (+55% r/r) oraz dodatni wynik EBITDA
Medicalgorithmics S.A. reported estimated unaudited consolidated sales revenue of PLN 10.8 million for the second quarter of 2026, a 55% year-on-year increase, with a positive EBITDA of PLN 1.2 million. Revenue from the US market reached PLN 4.7 million.
2026-07

Frequently Asked Questions

Medicalgorithmics offers several key AI-powered solutions, including the DeepRhythm Platform (DRP), a cloud-based ECG analysis platform, and DeepRhythmAI (DRAI), FDA-cleared AI algorithms for real-time heart rhythm analysis. They also provide PocketECG for ambulatory monitoring and VCAST, an AI-based virtual cardiac stress test using CT data.
Medicalgorithmics' DeepRhythmAI (DRAI) and DeepRhythm Platform (DRP) are FDA-cleared and CE-certified, demonstrating adherence to medical device regulations. The company also emphasizes compliance with FDA requirements for manufacturing, labeling, and reporting, and has a Data Protection Officer to address data privacy concerns, including GDPR.
Yes, Medicalgorithmics' DeepRhythm Platform (DRP) is hardware-agnostic and designed for seamless integration with third-party software and various ECG monitoring devices. This allows healthcare providers to leverage their AI algorithms without requiring a complete overhaul of existing equipment.
Medicalgorithmics has shifted its business model to focus on selling standalone AI analytical software products that integrate with third-party medical equipment. Their contracts often include guaranteed monthly minimums, and the company aims to generate recurring revenue streams from these high-margin AI algorithms and diagnostic software.
While specific details on training programs are not extensively publicized, Medicalgorithmics provides general contact information for inquiries, including dedicated contacts for partnerships and clinical research. They aim to support healthcare professionals in utilizing their advanced diagnostic solutions effectively.
Medicalgorithmics has established numerous partnerships, including collaborations with companies like Zenicor Medical Systems AB and livetec Ingenieurbu00fcro GmbH for integrating their AI software with various ECG systems. They also partner with leading U.S. cardiac tech providers and research institutions globally to advance their diagnostic solutions.
Medicalgorithmics, established in 2005, has shown recent dynamic growth with increased revenue and positive EBITDA in recent quarters, driven by strong sales in the US market. A strategic investor, Biofund Capital Management LLC, has also contributed to greater financial stability and a path for dynamic growth.

Related Companies

CAIMed, the Lower Saxony Center for Artificial Intelligence and Causal Methods in Medicine, is a research institution dedicated to advancing personalized healthcare through innovative AI and causal methodologies. The center aims to address widespread diseases such as cancer, cardiovascular diseases, and infections by linking research data, clinical data, and patient care data. This integrated approach, […]

Autoderm is a health technology company that provides a CE-marked AI dermatology screening API designed to analyze smartphone photos for various skin conditions. The company’s AI models are trained on a proprietary database of amateur smartphone images of skin diseases and are accessible via an API that can be integrated into various platforms, including electronic […]

OCTA is an AI-powered finance automation platform that aims to streamline financial operations and accelerate cash flow for businesses, particularly SMEs and enterprises in the Middle East, with a strong presence in the UAE and Saudi Arabia. The platform utilizes AI agents to automate tasks across the entire contract-to-cash cycle, including contract creation, e-signing, invoicing, […]

Skin Analytics is a British health technology company dedicated to the early and accurate diagnosis of skin cancer, aiming to reduce mortality from the disease. They achieve this through their flagship product, DERM, an AI-powered medical device. DERM is designed to provide dermatologist-quality skin cancer assessments, making them more accessible and reducing the burden on […]

MedTalk AI is an Australian-based healthcare AI company focused on streamlining clinical documentation for physicians and other healthcare professionals. The company’s flagship product is an ambient AI medical scribe that listens to real clinical conversations and converts them into structured, accurate notes in real-time. This technology aims to free clinicians from the burden of manual […]

allergoSMART is a healthcare AI company that offers the world’s first AI-based complete solution for personalized mite allergen avoidance. The company’s system, allergoSMART, provides a unique AI digital solution for individuals with dust mite allergies, combining targeted prevention and treatment through comprehensive home environment optimization. [3] It integrates symptom tracking, telemedicine, and air purification into […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.